Canadian researchers found that stroke patients with prediabetes who received pioglitazone had a 40% reduction in the composite outcome of myocardial infarction and stroke, and a 33% reduction in stroke alone over 4.8 years, compared with those on placebo, according to a study published in JAMA Neurology and presented at the International Stroke Conference. Based on 3,876 patients, findings revealed that patients with good adherence also had an 80% reduction in new-onset diabetes.
Pioglitazone tied to better health outcomes in stroke, prediabetes
Sign up for DiabetesPro SmartBrief
News for diabetes health professionals
Get the intelligence you need: news and information that is changing your industry today, hand-curated by our professional editors from thousands of sources and delivered straight to your inbox.